Covidien launches EverFlex self-expanding peripheral stent in Australia and New Zealand


Covidien has announced the launch of its EverFlex self-expanding peripheral stent with Entrust delivery system in Australia and New Zealand. The latest version of the EverFlex stent features the new Entrust delivery system, which enables physicians to consistently place stents with accuracy, while providing the ease of a one-handed device.

“It is impressive to see the existing EverFlex stent now available on an easy to use, low profile, triaxial designed delivery system,” says Michael Denton, associate professor, Epworth Hospital, Richmond. “With a lower profile, the puncture site is smaller, possibly resulting in fewer access site complications and faster ambulatory rates.”

The Entrust delivery system deploys the EverFlex stent, which is used to re-open narrowed (stenotic) regions of the superficial femoral and proximal popliteal arteries that supply blood to the legs. Narrowing of these arteries is associated with a condition known as peripheral arterial disease, where plaque builds along lining of the arteries, blocking blood flow to the legs. The 36-month results from the DURABILITY II study demonstrate that even in long, complex lesions, the EverFlex stent is able to sustain patency and durability. Furthermore, with the Entrust delivery system, physicians can deploy all sizes, up to 150 millimetre lengths, of the Covidien EverFlex stent on a low 5F profile with preserved radial force.

“Our Entrust delivery system allows for one-handed delivery of the EverFlex stent for treating patients with peripheral arterial disease,” says Mark A Turco, chief medical officer, Vascular Therapies, Covidien. “The design of the system is based on extensive physician feedback and procedural observation, and should allow for better performance during stent deployment.”